Achillion Pharmaceuticals, Inc.  

(Public, NASDAQ:ACHN)   Watch this stock  
Find more results for ACHN
9.23
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 2.65 - 16.87
Open     -
Vol / Avg. 0.00/3.68M
Mkt cap 1.09B
P/E     -
Div/yield     -
EPS -0.71
Shares 117.56M
Beta 1.96
Inst. own 94%
Aug 5, 2015
Q2 2015 Achillion Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 23, 2015
Achillion Pharmaceuticals Inc at JMP Securities Life Sciences Conference - 9:00AM EDT - Add to calendar
Jun 2, 2015
Achillion Pharmaceuticals Inc Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
May 19, 2015
Achillion Pharmaceuticals Inc Conference Call to Discuss collaboration arrangement with Janssen Pharmaceuticals Inc
May 18, 2015
Achillion Pharmaceuticals Inc at UBS Global Healthcare Conference
May 7, 2015
Q1 2015 Achillion Pharmaceuticals Inc Earnings Release
May 7, 2015
Achillion Pharmaceuticals Inc at Deutsche Bank Health Care Conference
Mar 5, 2015
Q4 2014 Achillion Pharmaceuticals Inc Earnings Release
Mar 4, 2015
Achillion Pharmaceuticals Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -35.42% -43.23%
Return on average equity -37.74% -46.56%
Employees 67 -
CDP Score - -

Address

300 George St
NEW HAVEN, CT 06511-6624
United States - Map
+1-203-6247000 (Phone)
+1-203-6247003 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ACHILLION PHARMACEUTICALS, INC. is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize treatments for infectious diseases. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus (HCV) infection that are administered once-daily, orally, and without ribavirin. Specifically, The Company is advancing ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, being prepared for Phase I clinical development, ACH-2684, a NS3/4A protease inhibitor, being prepared for Phase II clinical development.

Officers and directors

David I. Scheer Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Milind S. Deshpande Ph.D. President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Mary Kay Fenton CPA Chief Financial Officer, Senior Vice President
Age: 51
Bio & Compensation  - Reuters
David Apelian M.D., Ph.D. Executive Vice President, Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
Joseph Truitt Executive Vice President, Chief Commercial Officer
Age: 50
Bio & Compensation  - Reuters
Michael D. Kishbauch Director
Age: 65
Bio & Compensation  - Reuters
Jason S. Fisherman M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Gary E. Frashier Independent Director
Age: 78
Bio & Compensation  - Reuters
Kurt C. Graves Independent Director
Age: 47
Bio & Compensation  - Reuters
Dennis C. Liotta Ph.D. Independent Director
Age: 66
Bio & Compensation  - Reuters